Akero Therapeutics announced that it has commenced an underwritten public offering of $300M of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics’ EFX Shows Promise in Phase 2b MASH Study
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics price target raised to $43 from $40 at H.C. Wainwright
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
